Abstracts

RANDOMIZED CONTROLLED TRIAL OF ADJUNCTIVE ROSUVASTATIN FOR TUBERCULOSIS TREATMENT

In vitro and animal model data suggest statins may have benefit as adjunctive host-directed therapy for tuberculosis. Rosuvastatin has minimal interaction with rifampicin and is available in generic formulation. We hypothesised that rosuvastatin, at standard treatment doses used for lipid reduction, might accelerate sputum culture conversion. We randomised patients with rifampicin-susceptible TB (smear ?1 positive…

TB-PRACTECAL RESULTS: 24 WEEK ALL-ORAL REGIMENS FOR RIFAMPICIN RESISTANT TUBERCULOSIS

TB-PRACTECAL (NCT02589782) is a two-stage, multi-arm, randomised, controlled, open label phase II/III clinical trial evaluating the safety and efficacy of three 24-week all-oral regimens for the treatment of rifampicin resistant tuberculosis. We present results comprising all three investigational arms. Adults and children above 15 years were enrolled into the trial from six sites in Uzbekistan,…

INFECTIOUSNESS OF BREAKTHROUGH INFECTIONS AFTER VACCINATION AND NATURAL INFECTION

SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. Leveraging the national databases, effects of vaccination and of prior infection on SARS-CoV-2 infectiousness were investigated by comparing the RT-qPCR cycle threshold (Ct) values (inversely correlated with viral…

COVID-19 VACCINATION RATES IN A GLOBAL HIV COHORT

Little is known regarding global COVID-19 vaccination rates in people with HIV (PWH), a population with significant morbidity from COVID-19. The Randomized Trial to Prevent Vascular Events (REPRIEVE) is a global primary cardiovascular prevention trial among PWH (N=7770) with representation from >100 sites across twelve countries (Brazil, Botswana, Canada, Haiti, India, Peru, Spain, South Africa,…

AZD5582 PLUS SIV mAbs TO REDUCE TISSUE RESERVOIRS IN ART-SUPPRESSED MACAQUES

The ‘shock-and-kill’ HIV cure strategy involves latency reversal and immune-mediated clearance of infected cells. Our prior work showed systemic SIV latency reversal using the SMACm / cIAP antagonist AZD5582. Here, we investigated AZD5582 in combination with a cocktail of 4 rhesus-derived SIV Env-specific monoclonal antibodies (mAbs) to reduce viral reservoirs in ART-suppressed rhesus macaques (RMs).…

HIV-1 REMISSION WITH CCR5∆32∆32 HAPLO-CORD TRANSPLANT IN A US WOMAN: IMPAACT P1107

Background: HIV-1 cure has been reported in two men with HIV-1 and malignancy following CCR5∆32 homozygousallogeneic adult stem cell transplantation. We report on a woman in ART-free HIV-1 remission for 14months following CCR5∆32 homozygous cord blood (CB) and CD34-selected haploidentical stem celltransplant (haplo-cord SCT) for acute myeloid leukemia (AML). Methods: IMPAACT P1107 is an observational…